Author: slightbourne@noblecapitalmarkets.com

Gilead Deepens Arcus Ties With $320M Investment to Accelerate Cancer Immunotherapy Pipeline

Posted on by slightbourne@noblecapitalmarkets.com

Gilead Sciences and biotech partner Arcus Biosciences announced Tuesday an amended collaboration to accelerate development of their cancer immunotherapy programs, along with a $320 million equity investment by Gilead.

The deal builds on the companies’ 2020 partnership and boosts Gilead’s ownership in Arcus to 33% through an additional stake purchase at $21 per share. Gilead also gains a third seat on Arcus’ board, having their Chief Commercial Officer Johanna Mercier join as a director.

Strategic Focus on TIGIT

A key change is prioritizing late-stage studies for the anti-TIGIT antibody domvanalimab, the lead candidate from the collaboration. Arcus CEO Terry Rosen stated the partners want to “leverage their strengths and focus on efficiently advancing novel combinations.”

Domvanalimab is progressing in Phase 3 for non-small cell lung cancer and gastric/GEJ cancer. By accelerating these pivotal studies, expected to fully enroll by year-end, the drug could reach approval sooner if successful.

However, they are discontinuing the ARC-10 Phase 3 lung cancer trial to devote resources to the other domvanalimab studies targeting greater unmet need.

This streamlining highlights the companies’ faith in TIGIT’s potential but the necessity to optimize their most promising assets. TIGIT is an emerging immunotherapy target and domvanalimab a next-gen asset, so focusing late-stage research is prudent.

Quemliclustat Now Solo Arcus Program

Meanwhile, the planned Phase 3 study of Arcus’ CD73 inhibitor quemliclustat in pancreatic cancer will become an Arcus-only program, no longer jointly developed.

Again the theme is concentrating human capital and financial resources where they can make the biggest difference. For smaller Arcus, independence for some programs provides flexibility.

Arcus can also now fully control projects beyond domvanalimab and their PD-1 drug zimberelimab, which Gilead has options to license. This benefits Arcus’ broader pipeline and product vision.

Extends Arcus Cash Runway

Importantly, the $320 million cash infusion lengthens Arcus’ funding horizon until 2027 by their estimates. This enables advancing Phase 3 quemliclustat and AB154 studies plus potential commercial launch activities without financing concerns.

Any biotech developing novel drugs without revenue benefits immensely from having ample cash reserves. This partly protects Arcus from market volatility and general biotech funding challenges.

Gilead Building a Powerhouse

For Gilead, the enhanced Arcus alliance adds another pillar to their ambitions cancer franchise. The pharma giant has been aggressively wheeling and dealing to expand in oncology, now a key growth area.

Recent moves include the $21 billion Immunomedics acquisition and purchases of companies like Tango Therapeutics, Dragonfly Therapeutics, and Epizyme. The Arcus pact leverages access to next-generation immunotherapy science and pipeline.

Gilead is constructing a vertically integrated oncology player combining in-house and external innovation. Scale and synergies across R&D, manufacturing, and commercialization can accelerate targeted therapies to patients.

With collaborators like Arcus doing the early lifting, Gilead can then optimize late-stage studies and apply their regulatory expertise to reach approvals more quickly.

Overall the amended Arcus agreement highlights Gilead’s commitment to cancer and immunology while bolstering their presence in cutting-edge research like TIGIT inhibition. With the investment and restructuring, Gilead strengthens ties to Arcus’ science while keeping the biotech funded and focused. For both, it’s a win-win accelerating cancer drugs to market.

noble capital markets emerging growth virtual healthcare equity conference

Mark your calendars! Don’t miss Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on April 17-18. This exclusive virtual event connects investors with 50 leading public biotech, healthcare services, and medical device companies. Presenting company slots are available…Read More

JOLTS Report Shows Ongoing Labor Market Tightness

Posted on by slightbourne@noblecapitalmarkets.com

The latest Job Openings and Labor Turnover Survey (JOLTS) report released Tuesday by the Bureau of Labor Statistics showed job openings rose to 9.02 million in December, up from a revised 8.92 million in November. This was higher than economist forecasts of 8.75 million openings.

The December JOLTS report indicates ongoing tightness in the US labor market, as job openings remain stubbornly high even as the Federal Reserve has aggressively raised interest rates over the past year to cool demand and curb inflationary pressures.

On the surface, the rise in openings appears a negative sign for monetary policy aimed at loosening the jobs market. However, the increase was small, and openings remain well below the March 2023 peak of 11.9 million. The quits rate, which measures voluntary departures and is an indicator of workers’ confidence in ability to find new jobs, also edged down to 2.1% in December, though it remains elevated historically.

This suggests the Fed’s policy actions may be having a gradual effect, but the labor market remains tight overall. Layoffs also stayed low in December, with just 1.6 million separations due to layoffs or discharges during the month. The labor force participation rate ticked up to 62.3% in December, so labor supply is expanding somewhat, though participation remains below pre-pandemic levels.

For the Fed, the report provides ammunition on both sides of the debate as to whether a pause in rate hikes is warranted or further increases are needed to achieve a soft landing. Markets see a mixed bag, with the US dollar index largely unchanged on the day and Treasury yields seeing only slight moves following the release.

Impact on Economic Outlook

The bigger picture is that while job openings are declining, they remain unusually high, indicative of continued broad demand for workers across sectors like healthcare, manufacturing, and hospitality. Businesses appear eager to hire even amidst an economic slowdown and uncertainty about the outlook.

This need for workers will support consumer spending, the primary engine of US GDP growth, as long as hiring remains robust and layoffs low. But it also means upward pressure on wages as employers compete for talent, which could fuel inflation. Herein lies the conundrum for monetary policy.

The strength of the labor market is a double-edged sword – positive for growth in the near term, but concerning for the Fed’s inflation fight if it necessitates further large wage increases.

Chair Powell has been adamant the Fed’s priority is reducing inflation, even at the risk of economic pain. With the jobs market still hot in late 2023, further rate hikes seem likely at upcoming policy meetings absent a substantial cooling in inflation or rise in unemployment.

Payroll growth could slow in 2024 from levels above 400,000 per month in 2023, but demand remains too high relative to labor supply. The Fed wants meaningful softening in job openings and wage growth, which has yet to fully materialize. Unemployment would likely need to rise to the high 3% range or beyond to reduce wage pressures.

The JOLTS report provides important context on the state of the labor market amid crosscurrents in other economic data. Manufacturing has slowed and housing has declined, but consumers keep spending and job switching remains high. The Fed is unlikely to declare victory or shift to rate cuts with this conflicting mix of weak and resilient activity.

The path for monetary policy and markets will depend on which direction the trends in openings, wages, inflation and jobs growth tilt in coming months. For now, the JOLTS report gives the sense of an economy and labor market that are cooling gradually under the weight of higher rates rather than slowing precipitously.

WillScot Bolsters Modular Space Solutions With $3.8B McGrath Buyout

Posted on by slightbourne@noblecapitalmarkets.com

WillScot Mobile Mini Holdings Corp. announced Monday that it will acquire modular rental provider McGrath RentCorp in a $3.8 billion deal. The acquisition aims to solidify WillScot’s position as a leading provider of modular space and portable storage solutions across North America.

Under the terms of the agreement, McGrath shareholders will receive $123 per share, comprised of 60% cash and 40% WillScot stock. This reflects a 10.1% premium over McGrath’s share price as of January 26th. Once completed, McGrath shareholders will own approximately 12.6% of the combined company.

The deal comes as WillScot looks to expand its footprint and diversify its customer segments through McGrath’s complementary business. McGrath serves over 10,000 business customers with modular building leasing and sales solutions across the U.S.

According to WillScot CEO Brad Soultz, “The transaction will further accelerate our growth, with combined 2023 pro forma revenue of $3.2 billion and adjusted EBITDA of $1.4 billion, we will be on path to achieve a $700 million free cash flow run-rate twelve months after we close.”

WillScot expects to realize $50 million in run-rate cost synergies within two years following the close of the acquisition in Q2 2024. The company has a track record of successfully integrating past deals and meeting synergy targets.

The combined company will be able to cross-sell value-added products and services and roll out operations best practices across the broader customer base. It will also have increased scale and expanded infrastructure to accelerate organic growth strategies already in place.

Along with revenue and cost synergies, the deal provides WillScot with greater geographic diversification and depth in adjacent sectors like electronic test equipment rental through McGrath’s TRS-RenTelco business.

On the financial front, the combined company is projected to generate approximately $3.2 billion in revenue and $1.4 billion in adjusted EBITDA in 2023. It expects to produce around $700 million in free cash flow within twelve months after the merger is finalized.

To fund the cash component of the acquisition, WillScot has secured committed bridge financing of $1.75 billion, along with expanded capacity from its existing credit facilities. The company is committed to rapid deleveraging and plans to achieve a 3.0-3.5x net leverage ratio within a year post-close.

McGrath’s board has unanimously approved the transaction. With shareholder approval and regulator sign-off, the buyout is anticipated to close during Q2 2024. Until then, McGrath will operate as an independent, publicly traded company.

The acquisition is the latest in WillScot’s strategy to capitalize on demand growth for modular space and storage solutions. The company has acquired over 15 businesses since going public in 2017, including the transformative $1.2 billion merger with Mobile Mini in 2020.

For McGrath shareholders, the deal provides a significant premium and ongoing upside through ownership stake in WillScot. It also enables McGrath’s rental solutions to reach a wider audience through WillScot’s expansive branch network and customer base.

Science 37 to be Acquired by eMed in Deal to Expand Virtual Clinical Trials

Posted on by slightbourne@noblecapitalmarkets.com

Clinical research company Science 37 announced Monday that it has entered into a definitive agreement to be acquired by telehealth provider eMed in a deal valued at approximately $38 million. Under the agreement, eMed will commence a tender offer to purchase all outstanding shares of Science 37 stock for $5.75 per share in cash, representing a 21.3% premium over Science 37’s share price last week.

The deal will allow eMed to leverage Science 37’s remote clinical trial capabilities and proprietary Metasite technology platform to expand patient access and accelerate enrollment for clinical studies. Science 37’s decentralized clinical trial model enables patients to participate from home via telehealth, rather than having to travel to physical trial sites.

This acquisition comes at a pivotal time, as the biotech industry embraces virtual and hybrid trial designs in the wake of the COVID-19 pandemic. Science 37 was an early pioneer in decentralized trials, giving the company a first-mover advantage. According to Science 37 CEO David Coman, “eMed provides the greatest value to our stockholders, customers, patients, and employees. Stockholders will receive a premium, trial sponsors will gain greater access to patients, faster enrollment, and confidence in the Company’s capital position.”

For eMed, the deal significantly expands its digital healthcare footprint, adding Science 37’s network of telehealth investigators, coordinators, and software platform to its existing suite of at-home diagnostics and virtual care services. eMed was an early mover as well, having developed the first at-home COVID-19 test kit in 2020. Since then, the company has expanded into at-home testing and treatment for flu, UTIs, and other conditions.

The combined resources of both companies will provide end-to-end support for decentralized clinical trials, from patient recruitment to at-home sample collection to telemedicine visits. This could be a game-changer in improving patient diversity in trials and enabling studies focused on rare diseases or targeted therapies.

According to Science 37’s latest financial update, the company expects approximately $58-59 million in revenue for 2023 and over $50 million in cash reserves as of December 31, 2023. The company projected 2023 revenue of $50-60 million.

Science 37’s board of directors unanimously approved the acquisition deal with eMed. Major Science 37 shareholders, including Redmile Group, LLC, have also agreed to tender their shares in support of the acquisition.

The deal is expected to close in Q1 2024, pending tender of a majority of outstanding Science 37 shares and satisfaction of other customary closing conditions. Once completed, Science 37 will become a privately held subsidiary of eMed.

This Science 37 acquisition comes on the heels of eMed’s parent company, Evernow Inc., raising $100 million in Series B funding last March. The current deal highlights continued investor appetite for telehealth and digital health companies that are expanding access to care.

In fact, Noble Capital Markets will be hosting a Virtual Healthcare Conference from on April 17-18, 2024, featuring presentations from emerging growth companies in the healthcare sector. The conference will provide a platform for companies to showcase their innovations in digital health, telemedicine, medical devices and more.

The Science 37 and eMed deal also demonstrates the growing intersection between telehealth and clinical research. Other companies like Medable and Excelya are exploring how hybrid and decentralized trials can boost patient recruitment and retention. By meeting patients where they are, virtual trials enable more representative, diverse study populations.

While some industry experts say a hybrid approach will become the standard, decentralized trials are still a relatively new model. This acquisition provides eMed with a first-mover advantage, but expect other digital health companies to underscore their clinical trial offerings moving forward. In the meantime, all eyes will be on eMed and Science 37 as they pioneer the next generation of virtual clinical research.

Cooling Inflation Fuels Hope of Fed Rate Cuts Despite Economic Strength

Posted on by slightbourne@noblecapitalmarkets.com

The latest inflation reading is providing critical evidence that the Federal Reserve’s interest rate hikes through 2023 have begun to achieve their intended effect of cooling down excessively high inflation. However, the timing of future Fed rate cuts remains up in the air despite growing optimism among investors.

On Friday, the Commerce Department reported that the Fed’s preferred inflation gauge, the core personal consumption expenditures (PCE) index, rose 2.9% in December from a year earlier. This marked the first time since March 2021 that core PCE dipped below 3%, a major milestone in the fight against inflation.

Even more encouraging is that on a 3-month annualized basis, core PCE hit 1.5%, dropping below the Fed’s 2% target for the first time since 2020. The deceleration of price increases across categories like housing, goods, and services indicates that tighter monetary policy has started rebalancing demand and supply.

As inflation falls from 40-year highs, pressure on the Fed to maintain its restrictive stance also eases. Markets now see the central bank initiating rate cuts at some point in 2024 to stave off excess weakness in the economy.

However, policymakers have been pushing back on expectations of cuts as early as March, emphasizing the need for more consistent data before declaring victory over inflation. Several have suggested rate reductions may not occur until the second half of 2024.

This caution stems from the still-hot economy, with Q4 2023 GDP growth hitting a better-than-expected 3.3% annualized. If consumer spending, business activity, and the job market stay resilient, the Fed may keep rates elevated through the spring or summer.

Still, traders are currently pricing in around a 50/50 chance of a small 0.25% rate cut by the May Fed meeting. Just a month ago, markets were far more confident in a March cut.

While the inflation data provides breathing room for the Fed to relax its hawkish stance, the timing of actual rate cuts depends on the path of the economy. An imminent recession could force quicker action to shore up growth.

Meanwhile, stock markets cheered the evidence of peaking inflation, sending the S&P 500 up 1.9% on Friday. Lower inflation paves the way for the Fed to stop raising rates, eliminating a major headwind for markets and risk assets like equities.

However, some analysts caution that celebratory stock rallies may be premature. Inflation remains well above the Fed’s comfort zone despite the recent progress. Corporate earnings growth is also expected to slow in 2024, especially if the economy cools faster than expected.

Markets are betting that Fed rate cuts can spur a “soft landing” where growth moderates but avoids recession. Yet predicting the economy’s path is highly challenging, especially when it has proven more resilient than anticipated so far.

If upcoming data on jobs, consumer spending, manufacturing, and GDP point to persistent economic strength, markets may have to readjust their optimistic outlook for both growth and Fed policy. A pause in further Fed tightening could be the best-case scenario for 2024.

While lower inflation indicates the Fed’s policies are working, determining the appropriate pace of reversing course will require delicate judgment. Moving too fast risks re-igniting inflation later on.

The détente between inflation and the Fed sets the stage for a pivotal 2024. With core PCE finally moving decisively in the right direction, Fed Chair Jerome Powell has some latitude to nurse the economy toward a soft landing. But stability hinges on inflation continuing to cool amid resilient growth and spending.

For investors, caution and flexibility will be key in navigating potentially increased market volatility around Fed policy. While lower inflation is unambiguously good news, its impact on growth, corporate profits, and asset prices may remain murky until more economic tea leaves emerge through the year.

HEALWELL Makes Big Move into AI-Powered EHR Market Through Intrahealth Acquisition

Posted on by slightbourne@noblecapitalmarkets.com

Healthcare technology firm HEALWELL AI is starting 2024 off strong with the strategic acquisition of Intrahealth Systems, a global provider of electronic health record (EHR) software. This $24 million deal provides HEALWELL with a platform to showcase and scale up its impressive AI capabilities within the massive EHR solutions market.

For investors focused on healthcare tech and AI, this is an exciting play on some of the most promising trends reshaping the industry. As digital health and telemedicine expand rapidly, there is surging demand for next-gen EHR systems equipped with cutting-edge analytics and AI.

HEALWELL is aiming to be at the forefront of this movement by uniting its physician-designed AI with Intrahealth’s established EHR solutions and multi-national customer base.

With over 15,000 clinicians and millions of patients served across Canada, Australia, and New Zealand, Intrahealth boasts an impressive footprint and high-margin recurring revenue exceeding $12 million annually.

HEALWELL plans to turbocharge Intrahealth’s offerings by embedding its own AI-powered clinical decision support software. This technology has already demonstrated major promise in preventative care by enabling earlier disease detection and personalized interventions.

Integrating these AI capabilities into a widely adopted EHR platform like Intrahealth opens up tremendous possibilities to amplify outcomes and lower costs for healthcare providers globally. This direction aligns perfectly with growing adoption of value-based care models that prioritize proactive, tech-enabled, and patient-centric treatment.

For HEALWELL specifically, the benefits of acquiring Intrahealth extend well beyond the technology integration upside. This established player provides HEALWELL with a stable source of profitable SaaS revenue to complement its R&D pipeline. And Intrahealth’s international reach significantly expands HEALWELL’s total addressable market.

The deal also furthers HEALWELL’s broader acquisition-driven strategy focused on consolidating AI, data science, and digital health assets. Intrahealth delivers an ideal platform to demonstrate the power of HEALWELL’s innovations to a large audience of potential customers and partners.

With healthcare spending continuing to spiral globally, there is tremendous appetite for tools that can optimize care and reduce waste. This thematic tailwind, combined with Intrahealth’s impressive financials and HEALWELL’s tech prowess, makes the acquisition look like a savvy move.

Investors can gain valuable insights into the healthcare technology landscape at the upcoming Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference from April 17-18, 2024. This premier small-mid cap event will feature presentations from over 50 public emerging growth companies in the space.

The opportunity in AI-enhanced software platforms like EHR looks especially strong when considering the sheer size of the healthcare IT market. According to Grand View Research, this sector is projected to reach $230 billion by 2028, expanding at nearly 12% annually.

Within this landscape, EHR systems are a central focus, with MarketsandMarkets forecasting this specific niche to be worth $48 billion globally by 2027. First movers with differentiated offerings stand to grab significant market share as adoption of next-gen EHR accelerates.

By snapping up Intrahealth, HEALWELL is positioning itself as a frontrunner in this race to redefine the EHR status quo. Investors interested healthcare technology and AI should keep a close eye on how successfully HEALWELL leverages this strategic acquisition. The company’s progress integrating its robust AI into Intrahealth’s solutions will be an important proof point.

Overall, the Intrahealth deal provides HEALWELL with both an immediate boost in revenue and profitability, plus a long-term growth driver if the combined EHR/AI offering gains traction. This is exactly the sort of calculated, opportunistic move investors should want to see in an emerging healthcare technology leader like HEALWELL.

GC Oncology’s $380M IPO Kickstarts 2024 Biotech Market

Posted on by slightbourne@noblecapitalmarkets.com

The New Year has kicked off with a bang in biotech, as CG Oncology has completed the first initial public offering in the space for 2024. The cancer-focused biotech raised a whopping $380 million in its IPO on the Nasdaq, sailing past its initial target range of $181 million.

CG Oncology priced its shares at $19 apiece, above the $16-18 range it had set ahead of the IPO. The impressive deal is being viewed by many analysts and investors as a positive indicator that the biotech IPO market is rebounding in 2024 after a relatively slow 2023.

The robust demand for CG Oncology stock reflects renewed optimism and openness to investing in early-stage biotech companies, especially those with innovative science and strong leadership teams.

CG Oncology is developing a novel oncolytic virus therapy known as cretostimogene grenadenorepvec for the treatment of non-muscle invasive bladder cancer. Oncolytic viruses represent an exciting new approach in cancer treatment, wherein specially engineered viruses are able to infect and destroy cancer cells directly while also stimulating anti-tumor immune responses.

Cretostimogene grenadenorepvec is an adenovirus that has been engineered to replicate selectively in bladder cancer cells and stimulate the immune system by expressing granulocyte-macrophage colony-stimulating factor (GM-CSF). Early stage clinical data have shown promising signs of efficacy.

The company plans to use the IPO proceeds to fund a Phase 3 clinical trial of its lead candidate as well as earlier stage pipeline programs. Success in the Phase 3 study could support regulatory approval and commercialization.

CG Oncology was founded in 2018 by a veteran team of biotech entrepreneurs and scientists. The company pursued a pre-IPO crossover financing round in 2022, enabling it to build momentum heading into its public debut.

The IPO success places CG Oncology in a strong position to advance its pipeline. With the influx of capital, the company will be able to aggressively pursue its clinical development plans without relying heavily on external partners.

Moreover, the validation and visibility provided by being a public company can potentially help CG Oncology forge productive collaborations and access additional funding in the future.

Looking ahead, the positive investor response to CG Oncology seems likely to pave the way for more biotech IPOs in 2024. A robust IPO market provides fuel for innovation and discoveries that can transform patient lives.

The biotech sector sputtered in 2022, with only around 20 IPOs completed versus more than 50 in 2021. However, sentiment appears to be shifting, perhaps signaling sunnier days ahead.

In addition to favorable market conditions, biotech companies pursuing IPOs seem to be taking valuable lessons from 2022 by tightening focus on fundamentals like drug efficacy and visibility on clinical milestones.

Other than CG Oncology, a host of biotechs have already filed with SEC intentions to go public in 2024, spanning exciting areas like gene therapy, neurology, and synthetic biology.

With fresh capital and investor enthusiasm, the next generation of biotech companies can pursue ambitious goals to develop innovative medicines. More early-stage companies may also gain the funding needed to initiate or advance clinical trials.

CG Oncology’s big IPO pop reflects the right combination of cutting-edge science, unmet medical need, and strong leadership. This formula will likely be replicated by other emerging biotech stars in the making.

In all, the successful CG Oncology IPO kicks off 2024 as a promising year for biotech funding, innovation, and progress against once intractable diseases. Investors and industry observers will be tracking the IPO market closely through the year for signs of sustained momentum. If the appetite for compelling biotech stories persists, it could drive a much-needed renaissance helping to unlock new medical frontiers.

Mark your calendars! Don’t miss Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference April 17-18. This exclusive virtual event connects investors with 50 leading public biotech, healthcare services, and medical device companies.
Presenting company slots are available.

Meta and Microsoft Achieve $1 Trillion Milestones as AI Investments Pay Off

Posted on by slightbourne@noblecapitalmarkets.com

Two of the biggest tech giants, Meta and Microsoft, recently hit major market cap milestones as part of the ongoing record rally in tech stocks.

Meta’s market cap surpassed the $1 trillion during intraday trading on January 24th, marking the first time the company reclaimed this valuation since 2021. Meta previously hit the $1 trillion mark in September 2021 at the height of its stock’s popularity.

Driving Meta’s soaring stock price is a nearly 200% surge over the past year, as CEO Mark Zuckerberg enacted cost-cutting that included laying off over 20,000 employees. After its stock plummeted to a six-year low in 2022, Zuckerberg has described 2023 as a “year of efficiency.”

Shareholders are bullish on Meta’s focus on expanding its position in artificial intelligence. Last week, Zuckerberg revealed the company is ramping up AI investments, procuring hundreds of thousands of high-powered AI chips from Nvidia. This signals Meta is spending billions to compete in the red-hot AI space.

On the same day Meta topped $1 trillion, Microsoft also briefly surpassed the $3 trillion mark during trading on January 24th. This comes around two weeks after Microsoft temporarily overtook Apple as the world’s most valuable company in mid-January. While Apple has since regained the top valuation spot, Microsoft remains hot on its heels.

Fueling Microsoft’s continued share price gains is optimism around the company’s AI initiatives. Microsoft stock is up over 7% year-to-date amid strong demand for AI capabilities, especially in generative AI.

Analysts predict Microsoft will post a solid earnings beat for its upcoming quarterly report, citing its leadership in enterprise-level AI as a key advantage. Microsoft seems poised to capitalize on the explosion of interest in AI technologies like ChatGPT.

AI Arms Race

The back-to-back market cap milestones from Meta and Microsoft highlight the massive investments pouring into artificial intelligence right now.

With breakout successes like ChatGPT demonstrating new possibilities for generative AI, tech giants are racing to stake their claims. The companies leading development of advanced AI stand to reap substantial rewards.

Both Meta and Microsoft are positioning themselves at the forefront of this AI arms race. In addition to its major chip purchases, Meta recently unveiled its own chatbot project, BlenderBot. Microsoft is integrating generative AI into Bing search and other offerings.

The tech world’s strike into AI looks poised to pay off based on the positive investor sentiment boosting Meta and Microsoft’s valuations. However, the AI hype cycle could eventually lead to a correction for these high-flying stocks.

For now, shareholders seem willing to bet on the transformative potential of artificial intelligence. And the tech giants pouring money into AI research appear ready to capitalize on this enthusiasm.

Big Tech Boosts Markets

Meta and Microsoft reaching new market cap heights also highlights the outsized impact of Big Tech on the broader stock market. The performance of tech stocks is a key factor driving indexes like the S&P 500 to record levels.

Despite some pockets of weakness, optimism around AI and other emerging technologies continues fueling upward momentum. The Nasdaq index, heavily weighted toward tech, rose over 12% in 2023 even as the overall market declined.

This dynamic shows no signs of changing in 2024. Tech stocks led markets higher to begin the year, with the Nasdaq up close to 10% in January as of this writing. Stocks like Meta and Microsoft hitting new milestones reflects their leadership in this rally.

However, extended runs by Big Tech raise risks of overheating and heighten their influence on market swings. With Apple, Microsoft, Amazon, Alphabet and other tech giants comprising over 20% of the S&P 500, their performance significantly impacts overall returns.

Nonetheless, bullish sentiment toward AI and other disruptive tech breakthroughs appears likely to keep lifting valuations. As giants like Meta and Microsoft position themselves to capitalize on these trends, their gravity on markets looks set to rise.

NAYA Biosciences Strengthens Pipeline Through Acquisition of Gene Therapy Asset

Posted on by slightbourne@noblecapitalmarkets.com

NAYA Biosciences is expanding its clinical portfolio through the acquisition of an innovative gene therapy program from Florida Biotechnologies focused on treating rare mitochondrial diseases. This binding deal demonstrates NAYA’s strategy to rapidly build pipeline assets in high-potential areas like gene therapy.

NAYA has entered into a binding letter of intent to acquire Florida Biotechnologies for $20 million in NAYA shares, with potential milestone payments up to $5 million more. The deal specifically targets Florida Biotech’s clinical-stage gene therapy for Leber’s Hereditary Optic Neuropathy (LHON).

LHON is a rare mitochondrial genetic disease leading to progressive vision loss and blindness. There are currently no approved treatments. Florida Biotech’s AAV gene therapy aims to deliver functional copies of the mutated gene to restore cellular function.

Encouraging Safety Data

This therapeutic has already demonstrated encouraging safety data in a 28-patient Phase 1 trial conducted by Florida Biotech and the University of Miami’s Bascom Palmer Eye Institute. Building on this initial study, NAYA aims to accelerate Phase 2 development and provide early access to patients.

The therapy delivers the gene of interest inside an adeno-associated virus (AAV) vector containing a mitochondrial targeting sequence. This sequence enables delivery specifically to mitochondria, the key site of pathology in LHON and many other mitochondrial diseases.

Broad Applicability

While the lead indication is LHON, NAYA highlights this approach has potential for various mitochondrial orphan diseases. The platform’s strong intellectual property covers use of different AAV capsids and routes of administration.

This flexibility and the high unmet need enables a streamlined regulatory path, including Regenerative Medicine Advanced Therapy and priority review voucher opportunities. The technology has already received over $6 million in grant funding to date.

The asset aligns with NAYA’s focus on innovative regenerative medicine approaches with near-term clinical potential. Gene therapy represents a key component of NAYA’s strategy to build a pipeline addressing major unmet needs.

Expertise in Developing Gene Therapies

NAYA has extensive in-house expertise to advance the acquired AAV gene therapy through late-stage trials toward commercialization. For example, NAYA Chief Medical Officer Dr. Fred Grossman previously led development of the first approved gene therapy, Glybera, during his time at uniQure.

Florida Biotech co-founder Dr. Peter Kash also joins NAYA’s board, bringing over 36 years of biotech leadership experience, including developing and financing gene therapy pioneer Kite Pharma. This expertise will prove valuable for unlocking the platform’s full potential.

Execution of Broader Growth Strategy

NAYA Biosciences was formed earlier in 2023 through the merger of Clinigence Holdings and 4Front Biotech. This deal created a holding company structure to facilitate pipeline expansion through additional strategic acquisitions.

The Florida Biotechnologies program represents the next step in this growth strategy. NAYA plans to continue acquiring high-potential clinical assets to build a robust portfolio spanning gene therapy, oncology, fertility and other areas.

These efforts support NAYA’s overall mission of providing patients earlier access to transformative therapies. The company aims to take an entrepreneurial approach to aggressively advance new technologies through development.

Pending Merger to Unlock Public Markets

NAYA’s deal to acquire Florida Biotechnologies is contingent upon the completion of NAYA’s previously announced merger with fertility company INVO Bioscience, expected in Q1 2024.

The merger will create a publicly traded life sciences company under the INVO name, providing access to capital to support NAYA’s development programs and commercialization. The combined company is valued at over $100 million.

Conclusion

In summary, NAYA Bioscience’s move to acquire Florida Biotechnologies’ AAV gene therapy strengthens its pipeline and aligns with its strategy to focus on high-potential clinical assets. Leveraging its development expertise, NAYA is positioned to accelerate this innovative therapy toward commercialization and fill an important unmet need for patients with mitochondrial diseases.

Biotech Innovation: Emerging Cancer Vaccines and Investment Potential

Posted on by slightbourne@noblecapitalmarkets.com

Cancer research is rapidly evolving thanks to innovative biotech companies utilizing cutting-edge technology like artificial intelligence. One company at the forefront of this biotech revolution is Evaxion Biotech, which is developing novel personalized cancer vaccines powered by its proprietary AI platform.

As highlighted in a recent company press release, Evaxion is expanding its cancer vaccine pipeline to target a new class of AI-discovered tumor antigens called endogenous retroviruses (ERVs). ERVs are remnants of ancient viruses in our DNA that are often abnormally activated in cancer cells, making them visible targets for cancer vaccines.

Evaxion’s focus on ERV-based vaccines represents a breakthrough, transformative concept in cancer treatment. The company’s AI technology allows for identification of the most relevant ERV targets from patient genomic data, enabling truly personalized cancer vaccines.

Such precision vaccines could provide solutions for cancer patients unresponsive to current immunotherapies like checkpoint inhibitors. Evaxion aims to expedite development of this personalized vaccine approach, with initial proof-of-concept studies beginning mid-2024.

This innovation exemplifies the vast potential of emerging biotech companies to disrupt the cancer treatment landscape. Smaller firms like Evaxion can leverage cutting-edge technology like AI to uncover completely new therapeutic targets and strategies.

Powered by AI-Driven Discovery

Evaxion’s pivot to ERV-based vaccines is powered by its proprietary AI platform, AI-Immunology. This technology integrates advanced computational models that can decode the complexity of the human immune system’s interaction with cancer.

AI-Immunology allows rapid prediction and design of novel immunotherapy candidates. This is lightyears beyond traditional vaccine discovery dependent on lengthy trial-and-error experiments.

Evaxion’s AI technology provides a holistic, personalized approach to identify the most relevant targets and optimal vaccine strategies for each patient. This is key for developing effective cancer immunotherapies against the incredible heterogeneity seen across tumors and patients.

AI-Immunology represents a scalable, adaptable platform that can be applied to infectious diseases as well. Evaxion is also pursuing viral and bacterial vaccines powered by its AI discovery engine.

Other emerging biotech firms are also investing in AI-driven drug development, including companies like Recursion Pharmaceuticals, Exscientia, Insitro, and Valo Health. The massive potential of AI is transforming biopharmaceutical R&D.

Accelerating Innovation

Evaxion aims to accelerate innovation of its AI-discovered cancer vaccines. As indicated in its recent press release, the company has already initiated preclinical ERV vaccine studies, with plans for early proof-of-concept data by mid-2024.

This represents a rapid timeline from discovery to initial validation, enabled by AI-Immunology’s predictive modeling capabilities. Evaxion notes there is already significant interest around its ERV vaccine concept, which may help attract partners and investment to further accelerate development.

The company’s expedited progress exemplifies the ability of emerging biotech firms to move quickly from ideas to validation. Unencumbered by legacy infrastructure, these agile startups can transition discoveries into the clinic at unprecedented speed.

Investment Commentary

Evaxion’s pioneering AI platform and progress on its cancer vaccine pipeline highlights the compelling investment opportunities in emerging biotech companies.

These small firms offer differentiated technologies like AI-Immunology that enable transformative innovation not easily captured within larger pharmaceutical companies. First-mover advantage allows rapid value creation.

However, biotech investment carries significant risk. Clinical failures remain high across the industry. Diversification across a basket of emerging firms helps mitigate risks.

For investors interested in growth opportunities in small-cap biotech companies, the upcoming Noble Capital Markets Virtual Conference on April 17-18th features presentations from emerging healthcare and biotech companies.

The conference provides access to executive management teams from over 50 public microcap companies in the biotech, healthcare, and medical devices sector. It represents an excellent opportunity for exposure to innovative companies shaping the future of healthcare.

Biotech Revolution

We are in the midst of a biotechnology revolution led by innovative emerging firms. New technologies like AI and genomic profiling are unlocking unprecedented insights into disease biology and enabling personalized therapeutics.

Evaxion’s focus on AI-powered cancer vaccines represents just one example of transformative innovation occurring in the biotech sector. Other areas of rapid progress include gene therapies, cell therapies, targeted oncology treatments, and more.

Driven by these technological breakthroughs, the pace of biopharmaceutical advancement today is unprecedented. Venture capital investment in U.S. biotech startups hit record levels in 2021, topping $30 billion across over 1,000 deals.

The industry is positioned for continued expansion as emerging firms translate discoveries into new medicines. For investors, the high-growth biotech sector warrants attention despite its inherent risks.

Careful selection of companies with differentiated technologies like Evaxion’s AI platform can yield exciting returns. Ongoing evaluation of clinical execution remains key, as early scientific promise must still translate to real-world efficacy.

Overall, the biotech arena offers fertile ground for investment in innovation. The upcoming Noble Capital Markets Virtual Healthcare Conference highlights the wealth of emerging firms driving the biotechnology revolution.

Inhibrx Sells Lead Asset INBRX-101 to Sanofi for Up to $2.2 Billion

Posted on by slightbourne@noblecapitalmarkets.com

Biotechnology company Inhibrx announced today that it has entered into a definitive agreement to sell its lead therapeutic candidate, INBRX-101, to French pharmaceutical giant Sanofi in a deal valued at up to $2.2 billion.

INBRX-101 is a recombinant alpha-1 antitrypsin (AAT) therapy being developed for the treatment of alpha-1 antitrypsin deficiency (AATD), a rare genetic disorder that can cause severe lung and liver disease. Under the terms of the agreement, Sanofi will acquire Inhibrx through a merger in which Inhibrx shareholders will receive $30 per share in cash, a contingent value right (CVR) worth up to $5 per share, and one share in a new publicly traded company called Inhibrx Biosciences for every four shares of Inhibrx held.

Inhibrx Biosciences will retain all of Inhibrx’s pipeline assets and infrastructure outside of INBRX-101. This includes several early-stage therapeutic candidates such as INBRX-105 for solid tumors, INBRX-106 for hematologic malignancies, and INBRX-109 for conventional chondrosarcoma. The new company will receive $200 million in cash funding from Sanofi and begin trading publicly after the completion of the merger.

The total potential value of the upfront cash payment, CVR, and Inhibrx’s debt assumption implies an aggregate transaction value of approximately $2.2 billion. Inhibrx shareholders will also own 92% of the equity in the newly formed Inhibrx Biosciences, which will provide opportunities for future value creation.

The acquisition provides Sanofi with full rights to develop and commercialize INBRX-101 globally. The drug candidate is currently in a registrational Phase 2/3 trial evaluating its safety and efficacy in patients with AATD. Inhibrx believes INBRX-101 has multi-billion dollar peak sales potential if approved, which likely drove Sanofi’s interest in the asset.

Inhibrx’s innovative AAT therapy utilizes the company’s novel therapeutic protein engineering capabilities. INBRX-101 is designed to maintain the stability and activity of AAT, potentially enabling less frequent dosing than current AAT therapies. This next-generation approach could position INBRX-101 as a best-in-class treatment option for AATD.

The proposed transaction has been unanimously approved by the boards of directors of both companies and is expected to close in Q2 2024, subject to Inhibrx shareholder approval, regulatory clearances, and other customary closing conditions. Until then, it will be business as usual for Inhibrx as it continues developing its pipeline assets.

For Sanofi, the acquisition expands its portfolio in rare diseases while strengthening its capabilities in protein sciences and engineering. Adding INBRX-101 provides Sanofi with a promising late-stage candidate that can leverage its expertise and infrastructure in pulmonary diseases. Sanofi has been active on the deals front lately, including a recent $3.2 billion deal for Amunix Pharmaceuticals, as it refreshes its pipeline.

Meanwhile, the new Inhibrx Biosciences will emerge as an up-and-coming biotech with strong financial backing, a seasoned management team, and innovative technology platforms. The company will continue operating under the Inhibrx name and leadership. This strategic deal allows Inhibrx to unlock significant value from its lead program while retaining its other assets and resources to drive future growth.

The transaction is a win for both parties, providing Sanofi with a potential blockbuster drug and Inhibrx shareholders with an attractive return and ongoing upside through Inhibrx Biosciences. It demonstrates the broader trend of big pharma leveraging M&A to access innovative therapies from smaller biotech players. As Inhibrx’s programs advance, it will be interesting to see if Inhibrx Biosciences attracts buyout interest down the road. But for now, the company seems well-positioned to create value by advancing its earlier-stage pipeline.

Take a look at more emerging growth biotech companies by taking a look at Noble Capital Markets’ Senior Research Analyst Robert LeBoyer’s coverage universe.

Rotating Into Mining: The Overlooked Opportunity in Natural Resources

Posted on by slightbourne@noblecapitalmarkets.com

In the investing world, money often rotates between different sectors over time. After a long period of technology stocks dominating, we may now be entering a new cycle where mining and natural resource stocks start to outperform other industries and sectors. There are several compelling reasons mining could be the next big thing for investors.

First, demand is soaring for the critical minerals and metals used in electric vehicles, batteries, and clean energy. Metals like lithium, nickel, cobalt, and copper are essential for manufacturing electric car batteries, solar panels, wind turbines, and other green technologies. With many countries pushing for faster adoption of EVs and renewable power, demand for these key minerals is skyrocketing. Major automakers have announced ambitious electric vehicle plans, which requires secure access to raw materials. This imbalance between booming demand and limited supply bodes well for mining firms.

Additionally, the pandemic exposed risks of relying on a few countries for critical minerals. It revealed the need for domestic mining capacity to ensure stable access to essential inputs like lithium. For instance, the U.S. aims to boost domestic production of strategic minerals and reduce dependence on China. The EU also has a new plan to secure rare earth supplies within Europe. This focus on mineral independence is a plus for miners in North America and Europe.

Rising inflation and gold prices also bolster the case for mining stocks. With central banks printing huge amounts of money, many investors see gold as an inflation hedge. This has helped push gold prices to an 8-month high around $1900/ounce. Higher inflation tends to lift gold and silver prices as people flock to hard assets. Many miners produce both precious metals alongside base metals. They benefit from rising gold and silver prices.

Additionally, gold often rises when risks are high, like the current Russia-Ukraine and Israel-Gaza crises. Its safe haven appeal attracts buyers during geopolitical tensions. Between high inflation and geopolitical uncertainty, the macroeconomic environment seems favorable for both precious metal and base metal prices. This could kickstart a broad recovery across the mining sector.

The recent wave of mergers and acquisitions in mining also signals a positive shift. . In November 2023, Newmont Corporation completed its acquisition of Newcrest Mining Limited to create a leading global gold mining company with robust copper production. Just this month, Rio Tinto announced an $825 million lithium project purchase to support its battery materials business. These deals indicate big miners are positioning to capitalize on the electric vehicle revolution. Other companies like Century Lithium Corp. aim to produce lithium for the electric vehicle and battery storage market.

Additionally, mining stocks have held up well compared to the broader market’s decline. The global lithium stock index has surged over 110% in the past year. Many mining stocks linked to EVs have shown resilience amidst the tech stock plunge. This relative strength highlights the bullish outlook for miners enabling the energy transition. Noble Capital Markets’ investment banker Francisco Penafiel shared that “In the recent past, battery minerals have been getting the attention from investors, especially  critical metals such as lithium and cobalt. However, base metals like copper and nickel should also gain a healthy traction from the investment community, narrowing the existing valuation gap for junior miners,  due to the expected increase in their market demand as those are essential in the creation process of more efficient battery technologies”.   

After years of underperformance, mining stocks also look attractive relative to potential growth. For instance, the price-to-earnings ratio for diversified mining giant Glencore is under 6x, a bargain compared to high-flying tech stocks. While mining is volatile, long-term investors could be rewarded handsomely for their patience. The time seems ripe for mining stocks to revert upward after years of neglect.

Of course, risks exist like policy changes, permitting issues, cost inflation, and ESG concerns. But the overarching trend toward electrification seems unstoppable. While mining is cyclical, we appear to be entering an upcycle driven by underinvestment in new supply and exploding demand for the minerals needed to power the green transition.

Noble Capital Markets’ Senior Research Analyst, Mark Reichman states, “Our outlook for the mining sector remains favorable, particularly for the precious metals mining sub-sector. We believe growing electrification among developed nations and increased infrastructure spending bodes well for the long-term outlooks for metals such as copper, lithium, rare earths, and nickel. We think M&A activity will continue as large mining, energy, car manufacturers, and battery makers seek to de-risk their long-term strategies by ensuring long-term supplies of raw materials.”

In summary, mining stocks check many important boxes right now – strong demand drivers, favorable macro conditions, M&A activity, and reasonable valuations after a prolonged slump. The long-overlooked mining space seems poised for a renaissance, offering investors exciting opportunities. The winds appear to be shifting in favor of mining stocks as we embark on the new year and beyond. After years stuck in the doldrums, mining finally looks set to retake the spotlight.

Take a moment to take a look at Haynes International, a leading developer, manufacturer, and marketer of technologically advanced, nickel and cobalt-based high-performance alloys.

Alphabet Ends Relationship with AI Training Firm Appen in Major Blow

Posted on by slightbourne@noblecapitalmarkets.com

Tech giant Alphabet has decided to terminate its contractual relationship with Appen, an Australian company that has helped train many of Alphabet’s artificial intelligence products including the AI chatbot Bard.

Appen announced over the weekend that Alphabet notified them it will end all contracts effective March 19th. This is a massive blow to Appen, as Alphabet business accounts for around one-third of its total revenue.

Appen specializes in providing training data to tech firms to improve AI systems. It has helped train AI models for Microsoft, Apple, Meta, Amazon, Nvidia and others in addition to Alphabet. But the loss of the Alphabet contracts removes a huge chunk of its business.

Appen said it had no prior knowledge that Alphabet would end the relationship. The decision will impact thousands of subcontractors that Appen uses to source training data for Alphabet projects.

This termination caps what has been a very difficult stretch for the nearly 30-year-old Appen. The company has lost numerous major customers over the past two years as revenue declined 30% in 2023 and 13% in 2022.

Appen’s share price has also absolutely collapsed after peaking in 2020, falling over 99% from its high. Alphabet’s decision now deals a devastating blow to Appen’s attempts to turnaround the business.

Struggles Pivoting to Generative AI

Much of Appen’s struggles relate to challenges pivoting its offering to the new paradigm of generative AI. Models like ChatGPT and Google’s Bard work very differently than earlier AI systems. They rely more on processing power and less on human-labeled training data.

Former Appen employees said the company’s disjointed organizational structure and lack of quality control has hurt its ability to adapt its data services for generative AI. Appen touted work on search, translations, lidar, and more but large language models operate on a different scale.

For years Appen delivered solid growth supplying training data to Big Tech firms. But its business wasn’t built for the paradigm shift towards generative AI. Companies are spending far more on powerful AI chips from Nvidia and less on data from Appen.

Conflicts with Google

Interestingly, Appen has had public conflicts in the past with its now former major customer Alphabet. In 2019, Google mandated that contractors would have to pay workers at least $15 per hour. Appen did not meet that baseline wage requirement according to letters from some of its workers.

Earlier this year wage increases finally went into effect for Appen contractors working on Google projects like Bard. But other labor issues persisted. In June, Appen faced charges after allegedly firing six workers who spoke out about workplace frustrations.

This history of conflicts, along with Appen’s struggles to adapt to new AI needs, likely contributed to Alphabet’s decision to fully cut ties. The exact rationale remains unclear but the termination speaks to a relationship that was on shaky ground.

What’s Next for Appen

The loss of its Alphabet business leaves Appen in an extremely challenging position. In its filing, Appen said it will focus on managing costs and delivering quality AI training data to customers. But it has lost major customer after major customer in recent years.

Appen noted it will provide more details when it reports full year 2023 results in late February. But make no mistake, this termination represents a huge setback for its turnaround efforts.

For Alphabet, the move enables it to take greater control over how it sources training data and labeling for its AI systems. Relying less on third-party vendors aligns with its plans to invest heavily in developing its internal AI capabilities.

Meanwhile, the saga illustrates the rapid evolutions occurring in the AI sector. Generative models are transforming the field. For legacy players like Appen, adapting to stay relevant is proving enormously difficult.